# US 2025/0084416 A1 · Targeting of xkr8 in therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084416 A1
- Document ID: US20250084416A1
- Status: Published application
- Kind: A1
- Application number: 18/728,870
- Filed: 2022-09-19
- Published: 2025-03-13
- Earliest claimed: 2022-01-14
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Song Li; Yuang Chen
- Web page: https://patentgrep.com/patent/US20250084416A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6435: {the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin}
- A61K 47/6931: {the material constituting the nanoparticle being a polymer}
- A61P 35/00: Antineoplastic agents
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/351: Conjugate
- C12N 2310/3513: Protein; Peptide
- C12N 2320/31: Combination therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A therapeutic system or combination includes a first therapeutic agent to treat a disease condition and a second therapeutic agent adnrinistrable within a predetermined time of administration of the first therapeutic agent the second therapeutic agent inhibiting the function of Xkr8.

## Claims

### Claim 1

A therapeutic system or combination comprising a first therapeutic agent to treat a disease condition and a second therapeutic agent administrable within a predetermined time of administration of the first therapeutic agent, the second therapeutic agent inhibiting the function of Xkr8.

### Claim 2 (depends on 1)

The therapeutic system of claim 1 wherein the first therapeutic agent induces a therapeutic response which induces the expression of Xkr8 in addition to activation of Xkr8.

### Claim 3 (depends on 1)

The therapeutic system of claim 1 wherein the second therapeutic agent functions via RNA interference.

### Claim 4 (depends on 1)

The therapeutic system of claim 1 wherein the second therapeutic agent comprises Xkr8 siRNA.

### Claim 5 (depends on 4)

The therapeutic system of claim 4 wherein the first therapeutic agent is a chemotherapeutic agent.

### Claim 6 (depends on 4)

The therapeutic system of claim 4 wherein the system comprises nanostructures formed from self-assembly of a plurality of amphiphilic polymers comprising cationic groups, wherein a plurality of the first therapeutic agent, which is a hydrophobic or a lipophilic chemotherapeutic agent, is associated with a core of the nanostructures, and the second therapeutic agent comprising Xkr8 siRNA is added to the nanostructures and is associated with the cationic groups thereof.

### Claim 7 (depends on 6)

The therapeutic system of claim 6 wherein the nanostructures further comprise an application added to the nanostructures, the application comprising a negatively charged targeting agent selected from the group of a ligand for a cell receptor, a peptide, an aptamer, a polysaccharide, and an antibody.

### Claim at position 8

-13. (canceled)

### Claim 14 (depends on 2)

The therapeutic system of claim 2 wherein the targeting agent is a cell receptor and the cell receptor is a CD44 ligand.

### Claim 15 (depends on 14)

The therapeutic system of claim 14 wherein the application further comprises a hydrophilic polymeric compound.

### Claim 16 (depends on 15)

The therapeutic system of claim 15 wherein the hydrophilic polymeric compound includes a negative charge.

### Claim 17 (depends on 16)

The therapeutic system of claim 16 wherein the hydrophilic polymeric compound includes a conjugate of a negatively charged molecule and a hydrophilic polymer.

### Claim 18 (depends on 17)

The therapeutic system of claim 17 wherein the negatively charged molecule conjugated to the hydrophilic polymer is a CD44 ligand.

### Claim 19 (depends on 18)

The therapeutic system of claim 18 wherein the CD44 ligand is osteopontin, a collagen, a matrix metalloproteinase, chondroitin sulfate, hyaluronic acid, or a derivative thereof.

### Claim 20

(canceled)

### Claim 21 (depends on 15)

The therapeutic system of claim 15 wherein the second therapeutic agent comprising Xkr8 siRNA is added to the nanostructures before application of the negatively charged CD44 ligand and the hydrophilic polymeric compound.

### Claim 22 (depends on 15)

The therapeutic system of claim 15 wherein the first therapeutic agent is a small molecule therapeutic compound having a molecular weight below 1 kDa.

### Claim 23

(canceled)

### Claim 24 (depends on 15)

The therapeutic system of claim 15 wherein the cationic groups comprise an inherently cationic group or a group which forms a cation in vivo.

### Claim 25 (depends on 24)

The therapeutic system of claim 24 wherein the group which forms a cation in vivo is an amine group, wherein the amine group is an acyclic amine group, a cyclic amine group or a heterocyclic amine group.

### Claim 26 (depends on 25)

The therapeutic system of claim 25 wherein the amine group is selected from the group consisting of a metformin group, a morpholine group, a piperazine group, a pyridine group, a pyrrolidine group, piperidine, a thiomorpholine, a thiomorpholine oxide, a thiomorpholine dioxide, an imidazole, a guanidine, a biguanidine or a creatine.

### Claim 27 (depends on 17)

The therapeutic system of claim 17 wherein the hydrophilic polymer is selected from the group consisting of a polyalkylene oxide, a polyvinylalcohol, a polyacrylic acid, a polyacrylamide, a polyoxazoline, a polysaccharide and a polypeptide.

### Claim 28 (depends on 17)

The therapeutic system of claim 17 wherein the hydrophilic polymer is polyethylene glycol.

### Claim 29 (depends on 15)

The therapeutic system of claim 15 wherein a ratio of the negatively charged CD44 ligand to the hydrophilic polymeric compound is determined such that uptake of the nanostructures in the liver of a patient is maintained at a sufficiently low level to allow interaction of the negatively charged CD44 ligand with CD44 on a tumor remote from the liver.

### Claim 30 (depends on 16)

The therapeutic system of claim 16 wherein each of the plurality of amphiphilic polymers comprises a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one of the cationic groups, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one hydrophilic polymer.

### Claim 31

The therapeutic system 30 wherein the hydrophobic polymer backbone further comprises a pendant lipidic group.

### Claim at position 27

-52. (canceled)

### Claim 53

A formulation, comprising: nanostructures formed from self-assembly of a plurality of amphiphilic polymers, a plurality of a first hydrophobic or lipophilic therapeutic agent associated with a core of each of the nanostructures, and a second therapeutic agent which decreases the Xkr8 expression level or inhibits the function of Xkr8.

### Claim at position 29

-88. (canceled)
